GlassScriptPhysician profile
Sohail Khan
NPI 1194922765
$2,556.94
in general payments reported to CMS, 2019-2025
13 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.92 · 2020: $58.58 · 2021: $152 · 2022: $534 · 2023: $559 · 2024: $572 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $585.02 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $491.00 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $329.09 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $228.64 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $227.44 | 2021-2023 | Iluvien |
| Abbvie INC. | $179.75 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $179.55 | 2025 | Yutiq, Iluvien |
| Sandoz INC. | $108.76 | 2024-2025 | Cimerli |
| Optos, INC. | $80.88 | 2022 | |
| Coherus Oncology, INC. | $70.20 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $42.17 | 2023-2025 | Xipere |
| Boston Scientific Corporation | $17.42 | 2022 | |
| Allergan, INC. | $17.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.